BofA downgraded Fresenius Medical (FMS) to Underperform from Neutral with a price target of EUR 38, down from EUR 50, citing limited visibility on when patient volumes will recover and margin risks in 2025-26 due to ACA subsidies expiring and a mix shift to value-based care. The firm thinks upcoming potential catalysts are well appreciated and won’t drive meaningful near-term upside, the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Appoints Joseph Turk to Management Board
- Fresenius Medical appoints Joseph Turk as CEO, Care Enablement
- Cautious Hold Rating for Fresenius Medical Care Amidst Stagnant Growth and Uncertain Recovery
- Fresenius Medical Care Boosts Value-Based Care with Strategic Investment and Leadership Change
- Fresenius Medical downgraded to Sell from Neutral at UBS